Please assess the completion status of the following clinical trial:

Trial Title: GVAX vs. Placebo for MDS/AML After Allo HSCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* AML, CMML-with excess blasts, MDS-RAEB not in remission prior to leukemia cell harvest~* HLA 8/8 or 7/8 matched related or unrelated donor available~* ECOG performance status of 0-2~* Suitable candidate for myeloablative or reduced intensity conditioning allogeneic HSCT using PBSC or marrow as stem cell resource~* Normal organ function~Exclusion Criteria:~* Pregnant or breastfeeding~* Leukemia with active CNS involvement~* Positive HIV or HTLV-1 serology~* History of allergic reactions to compounds of similar chemical or biologic composition to GM-CSF~* Uncontrolled intercurrent illness~* History of different malignancy except if disease free for at least two years or cervical cancer in situ, basal or squamous cell carcinoma of the skin diagnosed and treated within the past two years~* Prior allogeneic transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GVAX (Type: ACTIVE_COMPARATOR): GVAX vaccine~Participants in the GVAX vaccine arm will undergo a conditioning regimen with busulfan and fludarabine prior to allogeneic hematopoietic stem cell transplant. Immediately after allogeneic hematopoietic stem cell transplant participants will start tacrolimus and methotrexate to prevent GVHD. GVAX arm participants meeting criteria to begin vaccinations will be administered the GVAX vaccine at established study time points.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo vaccine~Participants in the Placebo vaccine arm will undergo a conditioning regimen with busulfan and fludarabine prior to allogeneic hematopoietic stem cell transplant. Immediately after allogeneic hematopoietic stem cell transplant participants will start tacrolimus and methotrexate to prevent GVHD. Placebo vaccine arm participants meeting criteria to begin vaccinations will be administered the placebo vaccine at established study time points.

Based on this trial design, predict the completion outcome and termination type (if applicable).